The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice
Abstract
Nano-and microparticles of poly(lactide-co-glycolide) (PLGA) were formulated using poly(vinyl alcohol) (PVA) or hydrophobically modified hydroxyethylcellulose (HMHEC) or polyethyleneimine (PEI) as stabilizers. The uptake by murine Peyer's patches (PPs) and the binding to Peyer's patches-free tissue (PPFT) of these particles was investigated using fluorescence microscopy providing qualitative information about the tissue distribution of particles. Observations of intestinal cryo-sections showed significant discrimination in the uptake by PP of nano-and microparticles. The uptake by PPs of PLGA-PVA and PLGA-HMHEC nano-and microparticles, of negative and neutral zeta potential, respectively, was comparable, whereas a smaller number was observed in the case of nano-and microparticles of PLGA-PEI, positively charged. Moreover, particle uptake by PPs appeared to be strongly size-dependent. The number of particles of mean diameter around 0.3 and 1 microm observed in PPs was much greater than that of particles of diameter average close to 3 microm. However, in all cases, particles were found in the PPFT for at least 48 h. In conclusion, regarding the tissue samples we have observed, it appeared that the uptake of particles by PPs and binding to PPFT could be influenced by the physicochemical properties of the particles but this may not have been true at all sites of the intestine and may differ between animals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The particles’ size is pivotal for stability, distribution, release of the encapsulated antigens and induction of immune responses [36,37].”
From Use of lectin-functionalized particles for oral immunotherapy (2012) · cites this paper as [37]
Citations
Cites
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. D. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 1,008
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
Jani, P., Halbert, G. W., Langridge, J., & Florence, A. T. (1990) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1990.tb07033.x · Cited by 920
Biologically erodable microspheres as potential oral drug delivery systems
Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, M., et al. (1997) · Nature · doi:10.1038/386410a0 · Cited by 823
Eldridge, J. H., Hammond, C., Meulbroek, J. A., Staas, J. K., Gilley, R. M., & Tice, T. R. (1990) · Journal of Controlled Release · doi:10.1016/0168-3659(90)90133-e · Cited by 689
Jung, T. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00084-9 · Cited by 597
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
Florence, A. T. (1997) · Pharmaceutical Research · doi:10.1023/a:1012029517394 · Cited by 498
Redhead, H. M., Davis, S. S., & Illum, L. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00367-9 · Cited by 420
The Uptake and Translocation of Latex Nanospheres and Microspheres after Oral Administration to Rats
Jani, P. U., Halbert, G., Langridge, J., & Florence, A. T. (1989) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1989.tb06377.x · Cited by 394
The effect of physical barriers and properties on the oral absorption of particulates
Norris, D. A. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00037-4 · Cited by 261
Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epithelia
McClean, S., Prosser, E. S., Meehan, E., O'Malley, D., Clarke, N., Ramtoola, Z., & Brayden, D. J. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)10007-0 · Cited by 259
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–160 of 160
Mudassir, J., Darwis, Y., & Khiang, P. K. (2014) · International Journal of Polymeric Materials · doi:10.1080/00914037.2014.921919 · Cited by 11
Gaglio, S. C., Rosa, C. D., Piccinelli, F., Romeo, A., & Perduca, M. (2019) · Optical Materials · doi:10.1016/j.optmat.2019.05.034 · Cited by 10
Javaid, A., Imran, M., Latif, S., Hussain, N., Iqbal, H. M. N., & Bilal, M. (2022) · Journal of Materials Science · doi:10.1007/s10853-022-07679-7 · Cited by 9
“The nanoparticles which are soluble may get dissolved, metabolized and transported to blood and subsequently other organs, whereas the insoluble nanoparticles may be either retained in the airways and induce pulmonary effects [215].”
BackgroundEffective in-vivo utilization of lipid-based nanoparticles as drug carrier for carvedilol phosphate
Chakraborty, S., Shukla, D., Vuddanda, P. R., Mishra, B., & Singh, S. K. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01270.x · Cited by 9
“0 mm particle size.([2]) The basic mechanism by which lipid-based solid dispersions improve bioavailability of lipophilic drugs is by preventing their precipitation in the aqueous media of gastrointestinal tract.”
BackgroundChen, S., Zeng, F., & Fu, D. (2016) · Journal of Microencapsulation · doi:10.3109/02652048.2016.1156175 · Cited by 9
“It has been reported that PLGA nanoparticles could effectively cross some biological barriers and effectively deliver drug into cells (Panyam et al., 2003; Shakweh et al., 2005, Dinarvand et al., 2011).”
BackgroundBatch and microfluidic reactors in the synthesis of enteric drug carriers
Arruebo, M., & Sebastián, V. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818038-9.00008-9 · Cited by 10
Cell-penetrating Peptide-biodrug Strategy for Oral and Nasal Delivery: Review of Recent Findings
Khafagy, E., Kamei, N., & Takeda‐Morishita, M. (2012) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2012.06.013 · Cited by 8
Blanco-García, E., Guerrero-Callejas, F., Blanco-Méndez, J., Goméz-Couso, H., & Álvarez, A. L. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.06.023 · Cited by 8
Amekyeh, H., Billa, N., & Roberts, C. J. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.12.001 · Cited by 8
“Positively charged particles on the other hand were found to interact strongly with the mucus layer as the latter is negatively charged, resulting in an impeded uptake (Shakweh et al., 2005).”
BackgroundInfluentialHigashi, N., Kiyoshiro, N., Okumura, M., Nishimura, S., & Koga, T. (2019) · ACS Omega · doi:10.1021/acsomega.9b00899 · Cited by 8
Colloidal carriers for noninvasive delivery of insulin
Patil, N. H., & Devarajan, P. V. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-62614-1.00020-x · Cited by 7
Bridoux, A., Cui, H., Dyskin, E., Schmitzer, A. R., Yalçın, M., & Mousa, S. A. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.04.011 · Cited by 7
Tan, C., Billa, N., Roberts, C. J., & Scurr, D. J. (2014) · Nanomaterials · doi:10.3390/nano4040905 · Cited by 7
“Furthermore, solid lipid nanoparticles can enhance the lymphatic delivery of drugs which also contributes to bioavailability [10].”
BackgroundNovel noninvasive techniques in management of diabetes
Sameer, N. (2014) · Asian Journal of Pharmaceutics · doi:10.4103/0973-8398.139177 · Cited by 7
Development of an oral nanovaccine for dogs against Echinococcus granulosus
Leroux, M., Benavides, U., Hellel-Bourtal, I., Silvarrey, C., Milhau, N., Marchal, T., Bourgeois, S., Lawton, P., Briançon, S., Pétavy, A.-F., et al. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.09.012 · Cited by 6
Ostacolo, L., Russo, P., Rosa, G. D., Rotonda, M. I. L., Maglio, G., Nese, G., Spagnuolo, G., Rengo, S., Oliva, A., & Quaglia, F. (2008) · Macromolecular Bioscience · doi:10.1002/mabi.200700303 · Cited by 6
Liang, R., Dong, L., Deng, R., Wang, J., Wang, K., Sullivan, M., Liu, S., Wang, J., Zhu, J., & Tao, J. (2014) · European Polymer Journal · doi:10.1016/j.eurpolymj.2014.05.017 · Cited by 6
Nanoparticles for Oral Delivery of Insulin
Ribeiro, A. J., Seiça, R. M. F., & Veiga, F. (2013) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-6010-3_4 · Cited by 6
Grewal, T. K., Majeed, S., & Sharma, S. (2018) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_2004_15 · Cited by 6
Mucosal Vaccine Delivery and M Cell Targeting
Gupta, P. N. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_9 · Cited by 6
Morello, A. P., Forbes, N., & Mathiowitz, E. (2007) · Journal of Microencapsulation · doi:10.1080/02652040601058467 · Cited by 6
“In some systems, depending on the materials and methods used, surfactants or surface-stabilizing agents can readily affect the size (Blanco and Alonso 1998; Capan et al. 1999; Liu and Deng 2002; Shakweh et al. 2005) of drug-loaded particles.”
BackgroundMethodStable Recombinant Invasion Plasmid Antigen C (IpaC)-Based Single Dose Nanovaccine for Shigellosis
Baruah, N., Halder, P., Koley, H., & Katti, D. S. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00378 · Cited by 5
Charge Modification of Pharmaceutical Nanocarriers: Biological Implications
Nafee, N. A., Schneider, M., & Lehr, C. (2008) · Fundamental biomedical technologies · doi:10.1007/978-0-387-76554-9_11 · Cited by 5
Enhanced Bioavailability and Intestinal Uptake of Nanoparticles After Oral Delivery
Patel, M., & Sawant, K. K. (2022) · Springer eBooks · doi:10.1007/978-3-030-83395-4_21 · Cited by 4
Asthana, S., Gupta, P. K., Konwar, R., & Chourasia, M. K. (2013) · Journal of Nanoparticle Research · doi:10.1007/s11051-013-1864-2 · Cited by 4
“Preparation and characterization of NPs Effects of formulation variables on the PGNP properties Size and size distribution are important evaluation parameters as they have direct relevance with stability, cellular uptake, and drug release (Lamprecht et al. 2001; Shakweh et al. 2005).”
BackgroundNandagiri, V. K., Muttu, C., Daly, J. S., Ramtoola, Z., Ciardelli, G., & Montevecchi, F. M. (2012) · Cited by 4
Thool, S. A., & Pokharkar, V. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03260-y · Cited by 3
“This is likely due to reduced electrostatic repulsion between the negatively charged mucosal surfaces and the nanoparticle surface, thereby facilitating closer interaction and internalization [55, 56].”
Wilkhu, J. S., Vangala, A., Mohammed, A. R., & Perrie, Y. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5070-2_11 · Cited by 3
Mucosal vaccine delivery: is M cell-targeted delivery effective in the mucosal lumen?
Lo, D. D. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.740008 · Cited by 3
“Some steps in this direction have already been made [28,29]; indeed, some synthetic particles can induce immunity when administered by the mucosal route.”
BackgroundYu, D.-H., Zhang, Y., Zou, G., Cui, X., Mao, Z., & Gao, C. (2014) · Biointerphases · doi:10.1116/1.4894531 · Cited by 3
PLGA Nanoparticles for Oral Delivery: Nephrotoxicity and Pharmacokinetic Studies
Singh, N., Mishra, N., Raza, K., & Parashar, P. (2022) · Springer eBooks · doi:10.1007/978-3-030-83395-4_18 · Cited by 3
Liu, Z., Xu, N., Zhao, L., Yu, J., & Zhang, P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121078 · Cited by 2
PERSPECTIVES ON NANOPARTICULATE DELIVERY OF THERAPEUTIC PROTEINS BY ORAL ADMINISTRATION
Coué, G. M. J. P. C., & Engbersen, J. F. J. (2010) · Nano LIFE · doi:10.1142/s1793984410000109 · Cited by 2
Quantification of biodegradable PLGA nanoparticles for drug targeting
Ibrišimović, N., Al-Dubai, H., Kerleta, V., Gabor, F., & Pittner, F. (2010) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 2
Polymeric micro and nanoparticles as promising drug delivery vehicles: a review
Hussein, A. S., Abdullah, N., Fakhru', N. A., & Ahmadun, L. R. (2012) · International Journal of Nanoparticles · doi:10.1504/ijnp.2012.049909 · Cited by 2
Shubar, H. M. (2009) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-5393 · Cited by 2
“First, nanoparticles of negative ZP are better taken up through Peyer's patches in the gastrointestinal tract compared to positively charged nanoparticles (Shakweh et al 2005).”
BackgroundMurugeshu, A. (2009) · doi:10.31390/gradschool_theses.1703 · Cited by 2
Novel strategies to combat the antimicrobial resistance against Salmonella Typhi
Khare, P., Srivastava, A., Srivastava, R., & Jain, S. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106549 · Cited by 1
Polymeric Biomaterials for Controlled Drug Delivery
Mishra, M. (2015) · CRC Press eBooks · doi:10.1201/b19038-63 · Cited by 1
Nanotechnology for Oral Drug Delivery and Targeting
Reis, C. P., Martinho, N., & Damgé, C. (2016) · CRC Press eBooks · doi:10.1201/b19976-5 · Cited by 1
Polymer-based adjuvant requirements for vaccines
Soares, E. F. P., & Borges, O. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85941-7.00009-7 · Cited by 1
Nanomedicines to Improve Oral Delivery of Antiretroviral Drugs
Katari, O., & Jain, S. (2023) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-39020-3_9 · Cited by 1
Veiga, M.-D., Ruíz, R., Notario-Pérez, F., Martín-Illana, A., & Cazorla-Luna, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813627-0.00014-4 · Cited by 1
Nanotechnology for Oral Drug Delivery and Targeting
Reis, C. P., Martinho, N., & Damgé, C. (2016) · CRC Press eBooks · doi:10.1201/b19976-3 · Cited by 1
Developing Bilayer-Based Delivery Systems for Oral Delivery of Subunit Vaccines
Wilkhu, J. S., & Perrie, Y. (2014) · Advances in delivery science and technology · doi:10.1007/978-1-4939-1417-3_6
“In addition, work by Shakweh and co-workers also suggest that negatively charged or neutral particles in mice have a greater affinity for the Peyer’s patches than positively charged particles (Shakweh et al. 2005).”
BackgroundPharmaceutical Applications of Nanoparticle Carriers
Heurtault, B., Schuber, F. J., & Frisch, B. (2009) · Springer eBooks · doi:10.1007/978-3-540-88633-4_24
The potential of nanoscale carriers for drug delivery to intestinal mucosa and skin
Weiß, B. (2007) · Publications of the UdS (Saarland University) · doi:10.22028/d291-22374
Tran, H. T. T., Tran, P. H. L., Tran, T. T.-D., Lee, K.-H., & Lee, B.-J. (2009) · Journal of Korean Pharmaceutical Sciences · doi:10.4333/kps.2009.39.3.155
Bioresponsive nanoparticles based on poly(amidoamine)s for protein delivery
Coué, G. M. J. P. C. (2011) · doi:10.3990/1.9789036532105
Continuous Production of Stable Polymeric Nanoparticles for Oral Drug Delivery
Shen, H. (2013) · Figshare
Intestinal Uptake of Barley Protein Nanoparticles as Delivery Vehicles for Bioactive Compounds
Zhou, Y. (2013) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r31c1ts31
Micro- and Nanoparticles: Protein and Peptide Oral Delivery
Sajeesh, S., & Sharma, C. P. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120052532
(2015) · CRC Press eBooks · doi:10.1201/b18211-5
Development of an Oral Nanovaccine for Dogs Against Echinococcus GranulosusPreprint
Azzouz-Maache, S., Leroux, M., Benavides, U., Hellel-Bourtal, I., Silvarrey, C., Milhau, N., Marchal, T., Lawton, P., Briançon, S., Pétavy, A. F., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4068624
Polymeric Nano/Microparticles for Oral Delivery of Proteins and Peptides
Sajeesh, S., & Sharma, C. P. (2008) · CRC Press eBooks · doi:10.1201/9780849379741.ch7
Callet, A. (2010) · Serveur des thèses de l'Université de Strasbourg (University of Strasbourg)
Nanogels-Mediated Delivery of Vaccines
Halagali, P., Seenivasan, R., Datta, D., Ranade, S. D., & Tippavajhala, V. K. (2026) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-032-29006-9_8
Prajapati, C., Vyas, B., Chauhan, V., & Patel, M. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108886
Metadata
- Authors
- Shakweh, M., Besnard, M., Nicolas, V., & Fattal, E.
- Affiliations
- Université Paris-Sud (FR)
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2005-09
- Volume
- 61
- Issue
- 1-2
- Pages
- 1-13
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W1984520012
- Cited by
- 161
- References
- 27
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 7 · 2021: 4 · 2020: 2 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 11 · 2015: 7 · 2014: 18 · 2013: 8 · 2012: 14
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmaceutics and Biopharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- poly(lactic-co-glycolic acid), PLGA nanoparticles, PLGA microspheres, Peyer's patches, particle uptake, polyvinyl alcohol, polyethyleneimine, zeta potential, particle size, oral drug delivery, intestinal mucosa
- MeSH terms
- Administration, Oral, Animals, Drug Carriers, Drug Stability, Male, Mice, Inbred Strains, Microscopy, Electron, Scanning, Particle Size, Peyer's Patches, Polyglactin 910, Surface Properties, Nanostructures, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
